Replies to post #157926 on Enzolytics Inc (ENZC)

[foxi]

I did the analysis of some of ENZC's older filings back here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168639909

And everything else I referenced comes from the new quarterly:

https://www.otcmarkets.com/otcapi/company/financial-report/344142/content

There's a lot of newer company activity that may attract investors or financing partners. Applying their AI to diagnostic tests, applying their AI to veterinary medicine (shorter time to market than meds for humans), and the new IgA1/2 Clone 3 mAbs to name a few. Any one of those ventures could suddenly stick, and bring enough money to avert a R/S & dilution. We don't know all the details about Series B and Series E, maybe investors have to hold those until a company milestone and can't convert anyway...

But taking what we do know, there are a lot of convertible preferred shares with currently no room to convert. How can they make more room?



.